TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1091782
Abstract: Immune evasion through up-regulating checkpoint inhibitory receptors on T cells plays an essential role in tumor initiation and progression. Therefore, immunotherapy, including immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) and chimeric antigen… read more here.
Keywords: overcome barrier; promising target; target overcome; hematological malignancies ... See more keywords